TLR3 and lung carcinoma: In contrast, the down-regulation of FFAR2 in lung cancer did not attenuate the cAMP-AMPK-TAK1 signaling axis for the activation of NF-κB, thereby enhancing TLR2- and TLR3-induced lung cancer progression (Fig. 7M, right).